

RESEARCH

Open Access

# Analyses of clinicopathological, molecular, and prognostic associations of *KRAS* codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

Yu Imamura<sup>1†</sup>, Paul Lochhead<sup>1,2†</sup>, Mai Yamauchi<sup>1†</sup>, Aya Kuchiba<sup>1,3†</sup>, Zhi Rong Qian<sup>1</sup>, Xiaoyun Liao<sup>1</sup>, Reiko Nishihara<sup>1,3</sup>, Seungyoun Jung<sup>4</sup>, Kana Wu<sup>3</sup>, Katsuhiko Noshō<sup>5</sup>, Yaoyu E Wang<sup>6</sup>, Shouyong Peng<sup>1,7</sup>, Adam J Bass<sup>1,7</sup>, Kevin M Haigis<sup>8</sup>, Jeffrey A Meyerhardt<sup>1</sup>, Andrew T Chan<sup>4,9†</sup>, Charles S Fuchs<sup>1,4†</sup> and Shuji Ogino<sup>1,10,11\*†</sup>

## Abstract

**Background:** *KRAS* mutations in codons 12 and 13 are established predictive biomarkers for anti-EGFR therapy in colorectal cancer. Previous studies suggest that *KRAS* codon 61 and 146 mutations may also predict resistance to anti-EGFR therapy in colorectal cancer. However, clinicopathological, molecular, and prognostic features of colorectal carcinoma with *KRAS* codon 61 or 146 mutation remain unclear.

**Methods:** We utilized a molecular pathological epidemiology database of 1267 colon and rectal cancers in the Nurse's Health Study and the Health Professionals Follow-up Study. We examined *KRAS* mutations in codons 12, 13, 61 and 146 (assessed by pyrosequencing), in relation to clinicopathological features, and tumor molecular markers, including *BRAF* and *PIK3CA* mutations, CpG island methylator phenotype (CIMP), LINE-1 methylation, and microsatellite instability (MSI). Survival analyses were performed in 1067 *BRAF*-wild-type cancers to avoid confounding by *BRAF* mutation. Cox proportional hazards models were used to compute mortality hazard ratio, adjusting for potential confounders, including disease stage, *PIK3CA* mutation, CIMP, LINE-1 hypomethylation, and MSI.

**Results:** *KRAS* codon 61 mutations were detected in 19 cases (1.5%), and codon 146 mutations in 40 cases (3.2%). Overall *KRAS* mutation prevalence in colorectal cancers was 40% (=505/1267). Of interest, compared to *KRAS*-wild-type, overall, *KRAS*-mutated cancers more frequently exhibited cecal location (24% vs. 12% in *KRAS*-wild-type;  $P < 0.0001$ ), CIMP-low (49% vs. 32% in *KRAS*-wild-type;  $P < 0.0001$ ), and *PIK3CA* mutations (24% vs. 11% in *KRAS*-wild-type;  $P < 0.0001$ ). These trends were evident irrespective of mutated codon, though statistical power was limited for codon 61 mutants. Neither *KRAS* codon 61 nor codon 146 mutation was significantly associated with clinical outcome or prognosis in univariate or multivariate analysis [colorectal cancer-specific mortality hazard ratio (HR) = 0.81, 95% confidence interval (CI) = 0.29-2.26 for codon 61 mutation; colorectal cancer-specific mortality HR = 0.86, 95% CI = 0.42-1.78 for codon 146 mutation].

(Continued on next page)

\* Correspondence: shuji\_ogino@dfci.harvard.edu

†Equal contributors

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave., Room M422, 02215 Boston, MA, USA

<sup>10</sup>Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA

Full list of author information is available at the end of the article

(Continued from previous page)

**Conclusions:** Tumors with *KRAS* mutations in codons 61 and 146 account for an appreciable proportion (approximately 5%) of colorectal cancers, and their clinicopathological and molecular features appear generally similar to *KRAS* codon 12 or 13 mutated cancers. To further assess clinical utility of *KRAS* codon 61 and 146 testing, large-scale trials are warranted.

**Keywords:** Clinical outcome, Colon cancer, Genetic change, *RAF*, *RAS*

## Introduction

**Use of Standardized Official Symbols:** We use HUGO (Human Genome Organisation)-approved official symbols for genes and gene products, including *BRAF*; *EGFR*; *KRAS*; *PIK3CA*; all of which are described at [www.genenames.org](http://www.genenames.org).

Colorectal cancer represents a heterogeneous group of diseases, and its molecular classification is increasingly important. Colorectal cancers can be classified using mutations in oncogenes such as *KRAS*, *BRAF* and *PIK3CA* [1]. In addition, microsatellite instability (MSI) and epigenomic instability, such as the CpG island methylator phenotype (CIMP) and LINE-1 hypomethylation, have been associated with the oncogene mutations and clinical outcomes [1-4].

Approximately 30-40% of colorectal cancers harbor *KRAS* mutations, typically in codon 12 or 13 [5-9]. Features of colorectal cancers with *KRAS* codon 12 and 13 mutations include associations with cecal location [5,8], low-level CIMP (CIMP-low) [10-14], and *PIK3CA* mutation [15-18]. *KRAS* codon 12 and 13 mutations are widely accepted as a predictive biomarker of lack of response to anti-EGFR therapy in metastatic colorectal cancer [19-23], though a few exploratory studies suggest that codon 13 mutants may benefit from EGFR-targeted therapy [24,25].

*KRAS* codons 61 and 146 are additional hotspots for mutation in colorectal cancer, and data from a small number of studies suggest that *KRAS* mutation at these sites may predict resistance to anti-EGFR therapy [26-28]. Recently, Douillard et al., utilizing existing clinical trial data, reported that *KRAS* mutations in codons 61, 146, and 117, and mutations in *NRAS*, might identify patients with metastatic colorectal cancer who fail to derive benefit from panitumumab plus FOLFOX4 [29]. Despite growing clinical relevance, the clinicopathological and molecular features of colorectal cancers with *KRAS* codon 61 or 146 mutation remain largely unknown. It is of interest to examine the characteristics of colorectal cancers with *KRAS* mutations in codons 61 and 146, compared to those in codons 12 and 13, and *KRAS*-wild-type cases. In the near future, routine clinical testing of these additional *KRAS* codons may be warranted.

We therefore investigated the clinicopathological, molecular, and prognostic characteristics of tumors harboring *KRAS* codon 61 and 146 mutations, utilizing a molecular pathological epidemiology [30,31] database of 1267 colorectal cancers from two U.S. nationwide prospective cohort studies. We also performed a comprehensive review on

*KRAS* codon 61 and 146 mutations in colorectal cancer, and our curated literature data can be readily useful for public databases such as the COSMIC (Catalogue of Somatic Mutations in Cancer) database.

## Results

### *KRAS* codon 12, 13, 61 and 146 mutations, in relation to clinicopathological and molecular features

We detected *KRAS* mutations in 505 (40%) cases in 1267 colorectal cancers (Table 1). Codon 12 mutations were present in 344 cases (27%), codon 13 mutations in 115 cases (9.1%), codon 61 mutations in 19 cases (1.5%), and codon 146 mutations in 40 cases (3.2%). There were 493 cases with *KRAS* mutations identified in only one of codons 12, 13, 61 and 146, and 12 cases with *KRAS* mutations identified in two or more of the four codons (Table 1).

The baseline characteristics of study subjects are summarized in Table 2, according to tumor *KRAS* mutation status. Compared to *KRAS*-wild-type tumors, overall *KRAS*-mutated cancers were less likely to exhibit poor differentiation (5.8%,  $P < 0.0001$ ), MSI-high (6.2%,  $P < 0.0001$ ), and *BRAF* mutation (1.4%,  $P < 0.0001$ ), and more likely to demonstrate cecal location (24%,  $P < 0.0001$ ), CIMP-low (49%,  $P < 0.0001$ ), and *PIK3CA* mutation (24%,  $P < 0.0001$ ). Of note, these trends were generally evident across case groups with specific mutated codons (Table 2). *KRAS* mutation status was not significantly associated with sex, age, body mass index (BMI), year of diagnosis, family history of colorectal cancer, disease stage, peritumoral lymphocytic reaction, or tumor LINE-1 methylation level. There was no significant difference in any of the features between the cases with *KRAS* mutations identified in only one codon ( $N = 493$ ) and those with *KRAS* mutations identified in two or more codons ( $N = 12$ ), though statistical power was limited, given only 12 cases with *KRAS* mutations identified in multiple codons (Additional file 1: Table S1).

### *KRAS* mutation status and patient survival in *BRAF*-wild-type cases

To examine the prognostic role of *KRAS* mutation independent of *BRAF* mutation, within 1067 *BRAF*-wild-type cases (excluding *BRAF* mutants), we compared *KRAS*-mutated cancers to cases with wild-type *KRAS* in all four codons 12, 13, 61 and 146 (Additional file 2: Table S2). We evaluated clinicopathological, molecular and survival

**Table 1** Frequencies of *KRAS* mutations in 1267 colorectal cancer cases

Codon	Nucleotide change	Amino acid change	Codon change	No. of cases	Proportion among 1267 cases
Any	Any	Any	Any	505	40%
12	Any	Any	Any	344	27%
13	Any	Any	Any	115	9.1%
61	Any	Any	Any	19	1.5%
146	Any	Any	Any	40	3.2%
Mutations identified in only one of codons 12, 13, 61 and 146					
12	c.34G>A	p.G12S	GGT>AGT	12	1.0%
12	c.34G>C	p.G12R	GGT>CGT	7	0.6%
12	c.34G>T	p.G12C	GGT>TGT	43	3.4%
12	c.35G>A	p.G12D	GGT>GAT	157	12%
12	c.35G>C	p.G12A	GGT>GCT	20	1.6%
12	c.35G>T	p.G12V	GGT>GTT	93	7.3%
12	c.35_36delinsCA	p.G12A	GGT>GCA	1	0.1%
13	c.37G>C	p.G13R	GGC>CGC	1	0.1%
13	c.37G>T	p.G13C	GGC>TGC	2	0.2%
13	c.38G>A	p.G13D	GGC>GAC	103	8.1%
13	c.38G>T	p.G13V	GGC>GTC	2	0.2%
61	c.182A>G	p.Q61R	CAA>CGA	2	0.2%
61	c.182A>T	p.Q61L	CAA>CTA	4	0.3%
61	c.183A>C	p.Q61H	CAA>CAC	7	0.6%
60, 61	c.180_181delinsAA	p.Q61K	GGT + CAA>GGA + AAA	4	0.3%
146	c.436G>A	p.A146T	GCA>ACA	21	1.7%
146	c.436G>C	p.A146P	GCA>CCA	3	0.2%
146	c.437C>T	p.A146V	GCA>GTA	11	0.9%
Mutations identified in two or more of codons 12, 13, 61 and 146					
12, 13	c.35G>A, c.38G>A	p.G12D, p.G13D	GGT>GAT, GGC>GAC	4	0.3%
12, 13	c.35G>T, c.37G>T	p.G12V, p.G13C	GGT>GTT, GGC>TGC	1	0.1%
12,	c.35G>T,	p.G12V,	GGT>GTT, GGT + CAA>GGA + AAA	1	0.1%
60, 61	c.180_181delinsAA	p.Q61K			
12, 146	c.34G>C, c.436G>A	p.G12R, p.A146T	GGT>CGT, GCA>ACA	1	0.1%
12, 146	c.34G>T, c.436G>A	p.G12C, p.A146T	GGT>TGT, GCA>ACA	1	0.1%
12, 146	c.34G>T, c.437C>T	p.G12C, p.A146V	GGT>TGT, GCA>GTA	1	0.1%
12, 146	c.35G>T, c.436G>A	p.G12V, p.A146T	GGT>GTT, GCA>ACA	1	0.1%
13, 146	c.38G>A, c.436G>A	p.G13D, p.A146T	GGC>GAC, GCA>ACA	1	0.1%
12, 13, 61	c.35G>A, c.38G>A, c.183A>T	p.G12D, p.G13D, p.Q61H	GGT>GAT, GGC>GAC, CAA>CAT	1	0.1%

data of 51 cases with *KRAS* codon 61 and 146 mutations (Additional file 3: Table S3). There were 514 deaths, including 307 colorectal cancer-specific deaths, during a median follow-up of 11.7 years (interquartile range, 8.3-16.1 years) for censored cases.

The 5-year colorectal cancer-specific survival probabilities were 80.6% for cases with *KRAS*-wild-type/*BRAF*-wild-type tumors, 67.9% for cases with codon 12 mutations, 75.8% for cases with codon 13 mutations, 79.4%

for cases with codon 61 mutations, and 76.7% for cases with codon 146 mutations. Specific *KRAS* mutations were significantly associated with patient survival in Kaplan-Meier analysis (log-rank  $P = 0.0014$ , Figure 1). In multivariate analysis, compared to *KRAS*-wild-type/*BRAF*-wild-type tumors, we observed a significant prognostic association for *KRAS* codon 12 mutation [multivariate hazard ratio (HR) = 1.45; 95% confidence interval (CI), 1.12-1.87;  $P = 0.0048$ ; Table 3). However, neither


**Table 2 Clinicopathological, and molecular characteristics according to KRAS mutation status in 1267 colorectal cancer cases**

Clinicopathological or molecular feature	Total No.	KRAS		P (Wild-type vs. mutant)	KRAS mutations identified in only one codon				P (Across four mutants)
		Wild-type	Mutant		Codon 12	Codon 13	Codon 61	Codon 146	
Total No. of patients	1267	762	505		333	108	17	35	
Sex				0.0091					0.11
Male	573 (45%)	322 (42%)	251 (50%)		162 (49%)	59 (55%)	4 (24%)	19 (54%)	
Female	694 (55%)	440 (58%)	254 (50%)		171 (51%)	49 (45%)	13 (76%)	16 (46%)	
Mean age (years) ± SD	68.6 ± 8.7	68.4 ± 8.6	68.8 ± 8.8	0.47	69.5 ± 8.5	67.5 ± 9.2	70.0 ± 9.3	66.0 ± 9.8	0.065
BMI (kg/m <sup>2</sup> )				0.13					0.43
<30	1025 (81%)	607 (80%)	418 (83%)		278 (84%)	88 (81%)	11 (69%)	30 (86%)	
≥30	240 (19%)	155 (20%)	85 (17%)		54 (16%)	20 (19%)	5 (31%)	5 (14%)	
Year of diagnosis				0.26					0.032
Prior to 1998	640 (51%)	375 (49%)	265 (52%)		164 (49%)	63 (58%)	5 (29%)	23 (66%)	
1998 - 2006	627 (49%)	387 (51%)	240 (48%)		169 (51%)	45 (42%)	12 (71%)	12 (34%)	
Family history of colorectal cancer in first degree relative(s)				0.76					0.87
Absent	1026 (81%)	612 (80%)	414 (82%)		273 (82%)	89 (82%)	14 (82%)	27 (77%)	
Present in one first degree relative	179 (14%)	111 (15%)	68 (13%)		44 (13%)	15 (14%)	3 (18%)	5 (14%)	
Present in two or more first degree relatives	62 (5%)	39 (5%)	23 (5%)		16 (5%)	4 (4%)	0	3 (9%)	
Tumor location				<0.0001					0.50
Cecum	209 (17%)	90 (12%)	119 (24%)		79 (24%)	27 (25%)	4 (24%)	6 (18%)	
Ascending colon	262 (21%)	171 (23%)	91 (18%)		52 (16%)	25 (24%)	3 (18%)	7 (21%)	
Hepatic flexure to transverse colon	117 (9%)	78 (10%)	39 (8%)		26 (8%)	7 (6%)	4 (24%)	2 (5%)	
Splenic flexure to descending colon	90 (7%)	57 (8%)	33 (6%)		22 (7%)	7 (6%)	0	3 (8%)	
Sigmoid colon	297 (24%)	182 (24%)	115 (23%)		83 (25%)	22 (20%)	1 (5%)	8 (24%)	
Rectum	279 (22%)	176 (23%)	103 (21%)		67 (20%)	20 (19%)	5 (29%)	8 (24%)	
Disease stage				0.028					0.89
I	298 (23%)	190 (25%)	108 (21%)		77 (23%)	20 (19%)	4 (23%)	4 (11%)	
II	354 (28%)	230 (30%)	124 (25%)		77 (23%)	30 (28%)	5 (29%)	11 (32%)	
III	328 (26%)	183 (24%)	145 (29%)		97 (29%)	29 (27%)	3 (18%)	11 (32%)	
IV	173 (14%)	93 (12%)	80 (16%)		51 (15%)	18 (16%)	2 (12%)	6 (17%)	

**Table 2 Clinicopathological, and molecular characteristics according to *KRAS* mutation status in 1267 colorectal cancer cases (Continued)**

Unknown	114 (9%)	66 (9%)	48 (9%)		31 (10%)	11 (10%)	3 (18%)	3 (8%)	
Tumor differentiation				<0.0001					0.55
Well-moderate	1137 (90%)	663 (88%)	474 (94%)		314 (95%)	99 (92%)	16 (94%)	34 (97%)	
Poor	123 (10%)	94 (12%)	29 (6%)		17 (5%)	9 (8%)	1 (6%)	1 (3%)	
Peritumoral lymphocytic reaction				0.042					0.48
Absent-minimal	164 (14%)	96 (13%)	68 (14%)		47 (15%)	14 (13%)	2 (12%)	4 (12%)	
Mild	878 (72%)	515 (71%)	363 (75%)		237 (75%)	76 (71%)	12 (76%)	28 (85%)	
Moderate-marked	170 (14%)	117 (16%)	53 (11%)		32 (10%)	17 (16%)	2 (12%)	1 (3%)	
MSI status				<0.0001					0.078
MSI-low/MSS	1057 (85%)	587 (79%)	470 (94%)		315 (95%)	100 (94%)	14 (82%)	31 (89%)	
MSI-high	191 (15%)	160 (21%)	31 (6.2%)		16 (4.8%)	6 (5.7%)	3 (18%)	4 (11%)	
CIMP status				<0.0001					0.014
CIMP-negative	521 (44%)	311 (44%)	210 (44%)		139 (44%)	37 (36%)	8 (50%)	19 (54%)	
CIMP-low	460 (39%)	224 (32%)	236 (49%)		154 (49%)	59 (57%)	4 (25%)	16 (46%)	
CIMP-high	206 (17%)	172 (24%)	34 (7%)		21 (7%)	7 (7%)	4 (25%)	0	
<i>PIK3CA</i> mutation status				<0.0001					0.63
Wild-type	983 (84%)	632 (89%)	351 (76%)		242 (78%)	72 (74%)	12 (80%)	19 (68%)	
Mutant	190 (16%)	78 (11%)	112 (24%)		70 (22%)	25 (26%)	3 (20%)	9 (32%)	
<i>BRAF</i> mutation status				<0.0001					0.25
Wild-type	1078 (85%)	582 (77%)	496 (99%)		328 (99%)	106 (98%)	16 (94%)	35 (100%)	
Mutant	184 (15%)	177 (23%)	7 (1%)		3 (1%)	2 (2%)	1 (6%)	0	
Mean LINE-1 methylation level (%) (%) ± SD	62.7 ± 9.3	62.8 ± 9.6	62.5 ± 9.0	0.33	62.7 ± 9.2	61.5 ± 8.2	64.2 ± 10.1	63.1 ± 9.0	0.42

(%) indicates the proportion of cases with a specific clinicopathological, or molecular feature among each *KRAS* mutation status group. The *P*-value for significance was adjusted for multiple hypothesis testing to  $P = 0.05/14 = 0.0036$ . Thus, a *P*-value between 0.05 and 0.0036 should be regarded as of borderline significance. BMI, body mass index; CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable; SD, standard deviation.



**Figure 1** Kaplan-Meier curves for colorectal cancer patients with *BRAF*-wild-type tumors, according to tumor *KRAS* mutation status. (A) Colorectal cancer-specific survival. (B) Overall survival. Table indicates the number of patients who were alive and at risk of death at each time point after diagnosis of colorectal cancer.

mutation of *KRAS* codon 61 nor codon 146 was associated with patient outcome (Table 3). For cases with the 10 most common *KRAS* mutations across all four codons examined, those with the c.34G>T (p.G12C) mutation, and those with the c.35G>T (p.G12V) mutation experienced significantly higher colorectal cancer-specific mortality in Cox regression analysis [multivariate HR = 2.33; 95% CI, 1.36-3.99;  $P = 0.0021$  for c.34G>T (p.G12C); multivariate HR = 2.13; 95% CI, 1.47-3.09;  $P < 0.0001$  for c.35G>T (p.G12V); Table 3], even after adjusting a statistical significance level for multiple testing ( $P < 0.005$ ). None of the three most common *KRAS* mutations in codons 61 and 146 [c.183A>C (p.Q61H), c.436G>A (p.A146T) and c.437C>T (p.A146V)] was associated with patient prognosis (Table 3), although statistical power was limited. Subgroup analyses of stage I-II cases ( $N = 544$ , Additional file 4: Table S4), and stage III-IV cases ( $N = 414$ , Additional file 5: Table S5) yielded similar results, although statistical power was limited.

## Discussion

Although a number of studies have examined codon 61 or 146 hotspot mutations in colorectal cancer (Additional file 6: Table S6) [26-29,32-74], clinicopathological, molecular, and prognostic characteristics of those mutations have not been well investigated. Our data, from 1267 tumors, suggest that approximately 5% of all colorectal cancers harbor *KRAS* mutations in codon 61 or 146, and those colorectal cancers generally show similar characteristics to tumors with *KRAS* mutations in codon 12 or 13 (including associations with cecal location, CIMP-low and *PIK3CA* mutations).

A variety of methods have been used for *KRAS* codon 61 and 146 analyses (Additional file 6: Table S6) [26-29,32-74], which might have contributed to a wide variation in the prevalence of those mutations. Generally, nonsequencing methods make it cumbersome to confirm multiple independent mutations, and make it difficult to detect multiple variations at one allele without employing an expanded panel of probes or primers. Of the sequencing-based methodologies, pyrosequencing has been shown to be more sensitive than Sanger sequencing in paraffin-embedded archival tissue, with the capacity to reliably detect mutant alleles at low abundance (5-10% mutant), which is common in solid tumors [75].

The association between cecal cancers and *KRAS* mutations is intriguing. Emerging data suggest that gut luminal contents and microbiota, which change along bowel subsites, play important roles in colorectal carcinogenesis [8,76]. Our recent study on colorectal cancers in detailed subsites (from cecum to rectum) has shown that tumor molecular features (including *BRAF* mutation, MSI and CIMP-high) change along the bowel subsites, and that cecal cancers are associated with *KRAS* codon 12 and 13 mutations [5,8]. In our current study, cecal cancers appeared to be significantly associated with overall *KRAS* mutation status, and this trend was evident across all four mutated codons. Further studies are needed to elucidate why *KRAS* mutations, irrespective of mutated codon, are particularly common in cecal cancers.

Examining associations of tumor molecular features can provide insights into carcinogenesis processes, and

**Table 3 Colorectal cancer patient mortality according to KRAS mutation status in 1067 BRAF-wild-type cases**

KRAS	Total No.	Colorectal cancer-specific mortality			Overall mortality		
		No. of events	Univariate HR (95% CI)	Multivariate stage-stratified HR (95% CI)	No. of events	Univariate HR (95% CI)	Multivariate stage-stratified HR (95% CI)
Wild-type (codons 12, 13, 61 and 146)	582	144	1 (referent)	1 (referent)	258	1 (referent)	1 (referent)
All mutants together	485	163	1.46 (1.17-1.83) <i>P</i> = 0.0009	1.19 (0.94-1.51)	256	1.32 (1.11-1.57) <i>P</i> = 0.0018	1.14 (0.95-1.38)
Codons 12 and 13, and codons 61 and 146							
Codons 12 and 13	434	151	1.51 (1.20-1.90) <i>P</i> = 0.0004	1.27 (0.99-1.62)	235	1.36 (1.14-1.62) <i>P</i> = 0.0007	1.15 (0.95-1.40)
Codons 61 and 146	51	12	1.02 (0.57-1.85)	0.85 (0.47-1.56)	21	1.00 (0.64-1.56)	1.07 (0.68-1.68)
Codons 12, 13, 61 and 146							
Codon 12 mutants	328	121	1.64 (1.29-2.09) <i>P</i> < 0.0001	1.45 (1.12-1.87) <i>P</i> = 0.0048	183	1.45 (1.20-1.76) <i>P</i> = 0.0001	1.24 (1.01-1.52) <i>P</i> = 0.037
Codon 13 mutants	106	30	1.16 (0.78-1.72)	0.83 (0.55-1.25)	52	1.11 (0.82-1.49)	0.90 (0.66-1.24)
Codon 61 mutants	16	4	1.11 (0.41-3.01)	0.81 (0.29-2.26)	8	1.43 (0.71-2.90)	1.55 (0.75-3.18)
Codon 146 mutants	35	8	0.98 (0.48-2.01)	0.86 (0.42-1.78)	13	0.84 (0.48-1.48)	0.88 (0.50-1.56)
The 10 most common mutations in codons 12, 13, 61 and 146							
c.34G>A (p.G12S)	12	6	2.44 (1.07-5.54) <i>P</i> = 0.033	0.94 (0.39-2.23)	7	1.57 (0.74-3.33)	0.77 (0.35-1.70)
c.34G>C (p.G12R)	7	5	5.25 (2.13-12.9) <i>P</i> = 0.0003	3.44 (1.25-9.43) <i>P</i> = 0.017	6	4.69 (2.06-10.6) <i>P</i> = 0.0002	3.51 (1.42-8.70) <i>P</i> = 0.0067
c.34G>T (p.G12C)	42	16	1.70 (1.01-2.86) <i>P</i> = 0.044	2.33 (1.36-3.99) <i>P</i> = 0.0021	25	1.56 (1.03-2.35) <i>P</i> = 0.035	1.57 (1.02-2.42) <i>P</i> = 0.039
c.35G>A (p.G12D)	155	51	1.46 (1.06-2.01) <i>P</i> = 0.021	1.18 (0.84-1.66)	80	1.37 (1.06-1.76) <i>P</i> = 0.015	1.16 (0.89-1.51)
c.35G>C (p.G12A)	19	6	1.28 (0.56-2.90)	0.61 (0.26-1.42)	9	1.00 (0.51-1.95)	0.59 (0.30-1.17)
c.35G>T (p.G12V)	92	37	1.76 (1.22-2.52) <i>P</i> = 0.0024	2.13 (1.47-3.09) <i>P</i> < 0.0001	56	1.54 (1.16-2.06) <i>P</i> = 0.0033	1.54 (1.14-2.08) <i>P</i> = 0.0048
c.38G>A (p.G13D)	101	30	1.23 (0.83-1.82)	0.83 (0.55-1.26)	50	1.14 (0.84-1.54)	0.91 (0.66-1.25)

**Table 3 Colorectal cancer patient mortality according to *KRAS* mutation status in 1067 *BRAF*-wild-type cases (Continued)**

c.183A>C (p.Q61H)	7	2	1.06 (0.26-4.28)	0.46 (0.11-1.93)	4	1.28 (0.48-3.45)	1.16 (0.42-3.18)
c.436G>A (p.A146T)	21	3	0.55 (0.17-1.71)	0.50 (0.16-1.59)	5	0.45 (0.19-1.10)	0.51 (0.21-1.26)
c.437C>T (p.A146V)	11	4	1.94 (0.72-5.26)	1.77 (0.64-4.90)	7	2.02 (0.95-4.29)	2.10 (0.97-4.56)

The multivariate, stage-stratified Cox regression model initially included sex, age, body mass index, year of diagnosis, family history of colorectal cancer, tumor location, tumor differentiation, peritumoral lymphocytic reaction, microsatellite instability, CpG island methylator phenotype, *PIK3CA* mutation, and LINE-1 methylation. A backward elimination with a threshold of  $P=0.20$  was used to select variables in the final model. For the survival analysis of mutations in the two groups of *KRAS* codons (codons 12 and 13, and codons 61 and 146), the  $P$ -value for significance was adjusted for multiple hypothesis testing to  $P=0.05/2=0.025$ . Thus, a  $P$ -value between 0.05 and 0.025 should be regarded as of borderline significance. For the survival analysis of mutations in the four *KRAS* codons (12, 13, 61 and 146), the  $P$ -value for significance was adjusted for multiple hypothesis testing to  $P=0.05/4=0.013$ . Thus, a  $P$ -value between 0.05 and 0.013 should be regarded as of borderline significance. For the survival analysis of the 10 most common *KRAS* mutations, the  $P$ -value for significance was adjusted for multiple hypothesis testing to  $P=0.05/10=0.005$ . Thus, a  $P$ -value between 0.05 and 0.005 should be regarded as of borderline significance. CI, confidence interval; HR, hazard ratio.



is important in cancer research [77-83]. Previous studies have demonstrated that *KRAS* codon 12 and 13 mutations are associated with aberrant DNA methylation patterns, namely CIMP-low [10,11]. Our current study suggests that *KRAS* mutation, irrespective of mutated codon (statistical power was limited for codon 61 mutants), is associated with CIMP-low. It remains to be investigated why *KRAS* mutations are associated with CIMP-low in colorectal cancer. *KRAS* have been positively associated with *PIK3CA* mutations in colorectal cancer [15-18]. Our data suggest that *KRAS* mutations, irrespective of mutated codon, are associated with *PIK3CA* mutations. It has been reported that activated RAS signaling potentiates PI3K (phosphatidylinositol-4,5-bisphosphonate 3-kinase)/AKT signaling, which is augmented by the presence of *PIK3CA* mutations [84]. Considering a possible role for *PIK3CA* mutation as a predictive biomarker of response to adjuvant aspirin therapy in colorectal cancer [16], our finding may be of interest. *KRAS* codon 12 and 13 mutations have been inversely associated with *BRAF* mutation in colorectal cancer [17,26,33,41]. Our current data suggest that *KRAS* mutations, irrespective of mutated codon, are inversely associated with MSI-high and *BRAF* mutations in colorectal cancer. LINE-1 methylation level is a surrogate marker for global DNA methylation, and has been reported to be associated with MSI-high and CIMP-high in colorectal cancer [85]. This study showed that LINE-1 methylation level in average did not significantly differ according to *KRAS* mutation status.

Experimental studies are consistent with our observations that both *KRAS* codon 61 and 146 mutations can contribute to carcinogenesis in a similar manner to oncogenic mutations in codons 12 and 13. As *KRAS* codon 12 and 13 mutations, codon 61 mutation results in oncogenic RAS with impaired GTPase activity, resulting in constitutive activation [86,87]. *KRAS* codon 146 mutation-transfected HEK-293FT cells showed a larger amount of RAS-GTP compared to *KRAS*-wild-type-transfected cells [28]. These experimental data provide an insights into plausible functional roles of codon 61 and 146 mutations in carcinogenesis.

In our current survival analysis, there was no significant association between *KRAS* codon 61 and 146 mutations, and patient outcome. The prognostic value of *KRAS* mutation in colorectal cancer remains controversial [7,88-92]. Of note, in our current study, when we separately examined specific *KRAS* mutations, codon 12 mutations [especially c.34G>T (p.G12C) and c.35G>T (p.G12V)] were significantly associated with inferior survival, which is consistent with the 'RASCAL II' meta-analysis [88]. Accordingly, the prognostic associations of *KRAS* mutations in colorectal cancer may vary by specific mutation. Considered in conjunction with evidence that *KRAS* codon 61 and 146

mutations possess weaker transforming potential than codon 12 mutations [40], it may be the case that *KRAS* codon 61 or 146 mutation is not associated with patient prognosis. However, considering the limited case and event numbers for *KRAS* codon 61 and 146 mutations, our survival analyses should be considered exploratory. Additional larger studies, perhaps necessitating pooling of data, are required to definitively assess the prognostic roles codon 61 and 146 mutations in colorectal cancer.

Several studies have examined the predictive value of *KRAS* mutation in codon 61 and/or 146 in metastatic colorectal cancer treated with anti-EGFR therapy (cetuximab or panitumumab) [26-28,41,43]. Pentheroudakis et al. did not observe any association between *KRAS* codon 61 or 146 mutation ( $N=11$ ) and survival [41]. De Roock et al. showed that *KRAS* mutation in codon 61 ( $N=13$ ), but not that in codon 146 ( $N=11$ ), was significantly associated with lack of response to cetuximab [27]. Seymour et al. reported that *KRAS* codon 146 mutations ( $N=17$ ) were not associated with overall or progression-free survival [43]. In contrast, Loupakis et al. reported that, among *BRAF*-wild-type cancers, *KRAS* codon 61 or 146 mutant cases ( $N=8$ ) experienced a significantly lower response rate and progression-free survival [26]. Indeed, a few experimental studies also reported that tumors harboring *KRAS* mutations in codons 61 and 146 were resistant to anti-EGFR therapy [28,93]. In addition, a recent published study reported by Douillard et al., showed that *RAS* mutants ( $N=108$ ) with any mutation in *KRAS* codons 61, 117 and 146, or *NRAS* codons 12, 13, 61, 117 and 146, did not benefit from combined panitumumab plus FOLFOX4 chemotherapy [29]. In our dataset, due to scarcity of data on cancer treatment, we were unable to examine the important question of the predictive value of *KRAS* mutations in relation to anti-EGFR therapy. Further clinical studies in this area are clearly required.

The question arises as to whether it is worth investigating these relatively rare mutations in the clinical setting. Given that over 250,000 individuals each year die of colorectal cancer in Europe and the U.S., and most of these unfavorable outcomes are due to distant metastases, we estimate that every year approximately 10,000 cases have *KRAS* mutations in codon 61 or 146, and would be regarded as *KRAS*-wild-type through current *KRAS* codon 12 and 13 testing protocols. Considering that *KRAS* codon 61 and 146 mutations may also confer resistance to EGFR inhibitors [26-29,93], patients who have metastatic colorectal cancer with *KRAS* mutation in codon 61 or 146 could receive more tailored management through clinical testing of these additional *KRAS* codons.

A limitation of this study is the absence of data on *KRAS* codon 117 mutation and *NRAS* mutations. As a

result, we could not refine purer *RAS*-wild-type (both *KRAS*- and *NRAS*-wild-type in codons 12, 13, 61, 117 and 146), or examine clinicopathological, molecular and prognostic features of those whole *RAS* mutations in this study. Considering that *RAS* mutations in those codons have been reported to predict lack of response to anti-EGFR therapy in colorectal cancer [29], further studies are necessary to answer important questions about features across various *RAS* mutants. Nonetheless, *KRAS* codons 61 and 146 are the most frequent mutational hotspots after *KRAS* codons 12 and 13. In addition, our current analysis ( $N > 1200$ ) represents a large single study to date (Additional file 6: Table S6) [26-29,32-74], examining *KRAS* codon 61 and 146 mutations, in relation to other important molecular features in colorectal cancers, such as status of CIMP, MSI, *BRAF* and *PIK3CA* mutations. Sample size is a critical issue when assessing these relatively infrequent mutations. Indeed, smaller studies ( $N < 300$ , Additional file 6: Table S6) demonstrate considerable variability in the frequencies and distribution of reported *KRAS* mutations, ranging from 0.4% to 9.3% for *KRAS* codon 61 mutations, and from 1.3% to 6.6% for *KRAS* codon 146 mutations (Additional file 6: Table S6) [26-29,32-74]. Given the relatively low frequencies of these mutations, a large sample size is a prerequisite for assessing the prevalence of these mutations and their associations with other tumor molecular characteristics.

There are advantages in utilizing the molecular pathological epidemiology [30,31] database of the two U.S. nationwide prospective cohort studies to assess prevalence and associations of *KRAS* codon 61 and 146 mutations. Selection bias is an inevitable issue when analyzing cases identified from a few academic hospitals, since patients have selected hospitals based on referral, health insurance applicability, and/or their own preference. In contrast, a large population-based or multicenter study is desirable to decrease the degree of such selection bias. In this study, cohort participants who were diagnosed with colorectal cancer were treated at hospitals throughout the U.S., and thus constitute a more representative sample of colorectal cancers in the U.S. population than patients in a few academic hospitals.

## Conclusions

Our data from over 1200 colorectal cancers demonstrate that *KRAS* codon 61 or 146 hotspot mutations are present in approximately up to 5% of colorectal cancers, and those cancers exhibit similar clinicopathological and molecular features to cancers with *KRAS* codon 12 or 13 mutation. Our current findings suggest that additional large-scale studies are warranted to assess clinical utility of *KRAS* codon 61 and 146 testing in colorectal cancer.


## Materials and methods

### Study population

We utilized two prospective cohort studies, the Nurses' Health Study ( $N = 121,701$  women followed since 1976) and the Health Professionals Follow-up Study ( $N = 51,529$  men followed since 1986) [16]. Every two years, cohort participants have been sent follow-up questionnaires to identify newly diagnosed cancers in themselves and their first degree relatives. The National Death Index was used to ascertain deaths of participants as well as unreported lethal cancers. The cause of death was assigned by study physicians. Formalin-fixed paraffin-embedded tissue blocks were collected from hospitals where participants with colorectal cancer had undergone colorectal resection or diagnostic biopsy (for preoperatively-treated rectal cancers). We used 1267 colorectal cancer cases, diagnosed up to 2006, based on the availability of *KRAS* sequencing data. In order to examine the prognostic role of specific *KRAS* mutations, independent of *BRAF* mutation, *BRAF*-mutated cancers ( $N = 184$ ), cases with missing *BRAF* mutation status ( $N = 5$ ), and tumors with *KRAS* mutations identified in two or more of codons 12, 13, 61 and 146 ( $N = 11$ ) were excluded. As a result, a final total of 1067 *BRAF*-wild-type cases were used for survival analyses (Figure 2, Additional file 2: Table S2). Informed consent was obtained from all study subjects. This study was approved by the Human Subjects Committees at Harvard School of Public Health and Brigham and Women's Hospital. All clinicopathological and molecular analyses were performed blinded to other data, including patient outcome.

### Histopathological evaluation

Hematoxylin and eosin-stained sections of all cases were examined by a pathologist (SO) unaware of other data. Tumor differentiation was categorized as well-moderate



**Figure 2 Flow chart of the current study.** Cases with *BRAF* mutation ( $N = 184$ ) and those without available *BRAF* mutation data ( $N = 5$ ), were excluded from survival analyses. In addition, cases with *KRAS* mutations identified in two or more of codons 12, 13, 61 and 146 ( $N = 11$ ) were excluded, in order to assess a prognostic effect of specific *KRAS* mutations individually.

or poor (>50% vs. ≤50% gland formation). Peritumoral lymphocytic reaction was examined as previously described [94].

#### Sequencing of *KRAS* codons 61 and 146

DNA was extracted from paraffin embedded tissue as previously described, [16] and polymerase chain reaction (PCR) and pyrosequencing, targeted for *KRAS* codons 61 and 146, were performed. The PCR primers for amplifying *KRAS* codon 61 were, 5'-biotin-TGGAGAAACCTGTCTCTTG GATAT-3' (for forward primer), and 5'-TACTGGTCCCT CATTGCACTGTA-3' (for reverse primer), and those for *KRAS* codon 146 were 5'-ATGGAATTCCTTTTATT GAAACATC-3' (for forward primer), and 5'-biotin-TTG CAGAAAACAGATCTGTATTTAT-3' (for reverse primer). The sequencing primers were 5'-TCATTGCACTGTA CTCCTC-3' (for codon 61), and 5'-AATTCCTTTATT GAAACATCA-3' (for codon 146). Dispensation orders were designed such that all possible mutations would be detected (Additional file 7: Figure S1). All mutations were confirmed by replicate analysis.

#### Sequencing of *KRAS* codons 12 and 13, *BRAF*, and *PIK3CA*, and MSI analysis

We performed PCR and pyrosequencing targeted for *KRAS* (codons 12 and 13) [75], *BRAF* (codon 600) and *PIK3CA* (exons 9 and 20) as previously described [16]. MSI analysis was performed using 10 microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67 and D18S487) [8]. MSI-high was defined as instability in ≥30% of the markers. MSI-low (<30% unstable markers) tumors were grouped with microsatellite stable (MSS) tumors (no unstable markers) because we have previously demonstrated that these two groups show similar features [8].

#### Methylation analyses for CpG islands and LINE-1

Using validated bisulfite DNA treatment and real-time PCR (MethyLight), we quantified DNA methylation in eight CIMP-specific promoters [*CACNA1G*, *CDKN2A* (p16), *CRABP1*, *IGF2*, *MLH1*, *NEUROG1*, *RUNX3* and *SOCS1*] [8]. CIMP-high was defined as the presence of ≥6/8 methylated promoters, CIMP-low as 1-5/8 methylated promoters, and CIMP-negative as the absence of methylated promoters, according to established criteria [8]. In order to accurately quantify LINE-1 methylation levels, we used bisulfite pyrosequencing as previously described [8].

#### Statistical analysis

All statistical analyses were performed using SAS (Version 9.2, SAS Institute, Cary, NC). All *P*-values were two-sided. Univariate analyses were performed to investigate clinicopathological and molecular characteristics according to *KRAS* mutation status; a chi-square test or

Fisher's exact test was used for categorical data, while a Wilcoxon or Kruskal-Wallis test was applied to continuous data (age and LINE-1 methylation). To account for multiple hypothesis testing in associations between *KRAS* mutation and other 14 covariates, the *P*-value for significance was adjusted by Bonferroni correction to  $P = 0.0036 (=0.05/14)$ .

The Kaplan-Meier method and log-rank test were used to estimate survival distribution according to *KRAS* mutation status. Cases were observed until death, or January 1st 2011, whichever came first. For analyses of colorectal cancer-specific mortality, deaths as a result of other causes were censored. Cox proportional hazards regression models were used to compute mortality HRs for specific *KRAS* mutations. A multivariate model initially included the following clinicopathological and molecular variables with less than 10% of patients showing missing information among those we have previously published; sex, age (continuous), BMI (<30 vs. ≥30 kg/m<sup>2</sup>), year of diagnosis (continuous), family history of colorectal cancer in any first-degree relative (present vs. absent), tumor location (cecum vs. ascending colon to sigmoid colon vs. rectum), tumor differentiation (well-moderate vs. poor), peritumoral lymphocytic reaction (absent-minimal vs. mild-marked), MSI (high vs. low/MSS), CIMP (high vs. low vs. negative), *PIK3CA* mutation (present vs. absent) and LINE-1 methylation (continuous), with stratification by disease stage (I, II, III, IV or unknown) was performed using the "strata" option in the SAS "proc phreg" command. A backward elimination was performed with a threshold of  $P = 0.20$ , to avoid overfitting. Cases with missing information for any of the categorical covariates [BMI (0.2%), tumor location (1.0%), tumor differentiation (0.7%), peritumoral lymphocytic reaction (4.6%), MSI (1.6%), CIMP (6.7%), and *PIK3CA* (7.6%)], were included in the majority category of the given covariate to avoid overfitting. We confirmed that excluding cases with missing information in any of the covariates did not substantially alter results (data not shown). To account for multiple hypothesis testing in associations between *KRAS* mutations and patient outcome, the *P*-value for significance was adjusted by Bonferroni correction to  $P = 0.025 [=0.05/2, for the two groups of codons (codons 12 and 13, and codons 61 and 146)], P = 0.013 (=0.05/4, for the four codons), or P = 0.005 (=0.05/10, for the 10 most common mutations)$ . The proportionality of hazards assumption was satisfied by evaluating time-dependent variables, which were the cross products of the *KRAS* indicator variables and survival time (all *P*-values>0.07).

#### Literature search

A systematic literature search was performed in Pubmed, up to April 5, 2014, using combinations of the following search terms; *KRAS*, codon, (61 or 146), (colon, rectal or colorectal), and (cancer, carcinoma or adenocarcinoma). All eligible publications were retrieved, and their references

were checked to identify further relevant studies. In addition, we contacted some corresponding authors to obtain detailed data.

## Additional files

**Additional file 1: Table S1.** Clinicopathological, and molecular characteristics of *KRAS*-wild-type, only-one-*KRAS*-codon mutated, or two-or-more-*KRAS*-codons mutated cases.

**Additional file 2: Table S2.** Clinicopathological, and molecular characteristics according to *KRAS* mutation status in 1067 *BRAF*-wild-type cases.

**Additional file 3: Table S3.** Clinicopathological features of 51 *KRAS* codon 61 or 146 mutated cases in 1067 *BRAF*-wild-type cases.

**Additional file 4: Table S4.** Stage I-II, *BRAF*-wild-type colorectal cancer patient mortality according to *KRAS* mutation status.

**Additional file 5: Table S5.** Stage III-IV, *BRAF*-wild-type colorectal cancer patient mortality according to *KRAS* mutation status.

**Additional file 6: Table S6.** Previous studies examining *KRAS* codon 61 and 146 mutations in colorectal cancer.

**Additional file 7: Figure S1.** Pyrosequencing assay design and pyrograms for *KRAS* codons 61 and 146.

## Abbreviations

CI: Confidence interval; CIMP: CpG island methylator phenotype; HR: Hazard ratio; MSI: Microsatellite instability; MSS: Microsatellite stable; PCR: Polymerase chain reaction; PI3K: Phosphatidylinositol-4,5-bisphosphonate 3-kinase.

## Competing interests

ATC previously served as a consultant for Bayer Healthcare, Millennium Pharmaceuticals, and Pfizer Inc. This study was not funded by Bayer Healthcare, Millennium Pharmaceuticals, or Pfizer Inc. No other conflict of interest exists.

## Authors' contributions

YI, SO and KMH conceived of the study. YI, PL, MY, ZRQ, XL and KN carried out molecular analysis. YI and SO interpreted the data and drafted the manuscript. AK, RN, SJ, KW, YEW, SP and AJB helped the statistical analysis and participated in interpretation of data. JAM, ATC and CSF helped to draft the manuscript, and participated in interpretation of data. All authors read and approved the final manuscript.

## Acknowledgments

We deeply thank hospitals and pathology departments throughout the U.S. for generously providing us with tissue specimens. In addition, we would like to thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. This work was supported by U.S. National Institute of Health (NIH) grants [P01 CA87969 to S.E. Hankinson; P01 CA55075 to W.C. Willett; UM1 CA167552 to W.C. Willett; P50 CA127003 to CSF; R01 CA137178 to ATC; and R01 CA151993 to SO]; and by grants from the Bennett Family Fund and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance. ATC is a Damon Runyon Clinical Investigator. PL is a Scottish Government Clinical Academic Fellow and was supported by a Harvard University Frank Knox Memorial Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Author details

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave., Room M422, 02215 Boston, MA, USA.

<sup>2</sup>Gastrointestinal Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. <sup>3</sup>Department of Nutrition, Harvard School of Public

Health, Boston, MA, USA. <sup>4</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. <sup>5</sup>First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan. <sup>6</sup>Center for Cancer Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. <sup>7</sup>Cancer Program, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. <sup>8</sup>Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA. <sup>9</sup>Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA. <sup>10</sup>Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. <sup>11</sup>Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.

Received: 16 February 2014 Accepted: 7 May 2014

Published: 31 May 2014

## References

1. Lao W, Grady WM: Epigenetics and colorectal cancer. *Nat Rev Gastroenterol Hepatol* 2011, **8**:686–700.
2. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML: NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. *J Natl Compr Canc Netw* 2011, **9**(Suppl 5):S1–S32.
3. Colussi D, Brandi G, Bazzoli F, Ricciardiello L: Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. *Int J Mol Sci* 2013, **14**:16365–16385.
4. Bardhan K, Liu K: Epigenetics and colorectal cancer pathogenesis. *Cancers* 2013, **5**:676–713.
5. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD: Colorectal carcinomas with *KRAS* mutation are associated with distinctive morphological and molecular features. *Mod Pathol* 2013, **26**:825–834.
6. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruzsiewicz AR, Moore J, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM: *PIK3CA* and *PTEN* gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. *Clin Cancer Res* 2013, **19**:3285–3296.
7. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, Rutegard J, Palmqvist R: The prognostic role of *KRAS*, *BRAF*, *PIK3CA* and *PTEN* in colorectal cancer. *Br J Cancer* 2013, **108**:2153–2163.
8. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut* 2012, **61**:847–854.
9. Wangefjord S, Sundstrom M, Zendejrokh N, Lindquist KE, Nodin B, Jirstrom K, Eberhard J: Sex differences in the prognostic significance of *KRAS* codons 12 and 13, and *BRAF* mutations in colorectal cancer: a cohort study. *Biol Sex Differ* 2013, **4**:17.
10. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW: Genome-scale analysis of aberrant DNA methylation in colorectal cancer. *Genome Res* 2012, **22**:271–282.
11. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS: CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and *KRAS* mutations. *J Mol Diagn* 2006, **8**:582–588.
12. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH: Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. *Virchows Arch* 2009, **455**:485–494.
13. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. *Cancer Res* 2008, **68**:8541–8546.
14. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, Rutegard J, Oberg A, Van Gulpen BR: The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. *Clin Cancer Res* 2010, **16**:1845–1855.
15. Whitehall VL, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A, McKeone D, Faleiro RJ, Buttenshaw RL, Worthley DL, Nayler S, Zhao ZZ,

- Montgomery GW, Mallitt KA, Jass JR, Matsubara N, Notohara K, Ishii T, Leggett BA: **Oncogenic PIK3CA mutations in colorectal cancers and polyps.** *Int J Cancer* 2012, **131**:813–820.
16. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiha A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Noshio K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S: **Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.** *N Engl J Med* 2012, **367**:1596–1606.
17. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S: **KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.** *Lancet Oncol* 2011, **12**:594–603.
18. He Y, Van't Veer LJ, Mikolajewska-Handlich I, van Velthuysen ML, Zeestraten EC, Nagtegaal ID, van de Velde CJ, Marijnen CA: **PIK3CA mutations predict local recurrences in rectal cancer patients.** *Clin Cancer Res* 2009, **15**:6956–6962.
19. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zube A, Celik I, Rougier P, Ciardiello F: **Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.** *J Clin Oncol* 2011, **29**:2011–2019.
20. Bokemeyer C, Bondarenko I, Makshorn A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zube A, Koralewski P: **Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.** *J Clin Oncol* 2009, **27**:663–671.
21. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jasssem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: **Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.** *J Clin Oncol* 2010, **28**:4697–4705.
22. Custodio A, Feliu J: **Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.** *Crit Rev Oncol Hematol* 2013, **85**:45–81.
23. Reimers MS, Zeestraten ECM, Kuppen PJK, Liefers GJ, Velde CJH: **Biomarkers in precision therapy in colorectal cancer.** *Gastroenterol Rep* 2013, **1**:166–183.
24. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S: **Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.** *JAMA* 2010, **304**:1812–1820.
25. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E: **Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.** *J Clin Oncol* 2012, **30**:3570–3577.
26. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: **KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.** *Br J Cancer* 2009, **101**:715–721.
27. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeris KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al: **Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.** *Lancet Oncol* 2010, **11**:753–762.
28. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Hallilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB: **Genomic and biological characterization of exon 4 KRAS mutations in human cancer.** *Cancer Res* 2010, **70**:5901–5911.
29. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jasssem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD: **Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.** *N Engl J Med* 2013, **369**:1023–1034.
30. Ogino S, Chan AT, Fuchs CS, Giovannucci E: **Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.** *Gut* 2011, **60**:397–411.
31. Ogino S, Stampfer M: **Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology.** *J Natl Cancer Inst* 2010, **102**:365–367.
32. Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, Ma BB, Mak TW, Ng SS, To KF: **Characterization of rare transforming mutations in sporadic colorectal cancer.** *Cancer Biol Ther* in press.
33. Vaughn CP, Zobel SD, Furtado LV, Baker CL, Samowitz WS: **Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.** *Genes Chromosomes Cancer* 2011, **50**:307–312.
34. The Cancer Genome Atlas Network: **Comprehensive molecular characterization of human colon and rectal cancer.** *Nature* 2012, **487**:330–337.
35. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, Wolff HA, Herrmann MK, Beissbarth T, Becker H, Ried T, Ghadimi M: **KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.** *Radiother Oncol* 2010, **94**:76–81.
36. Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, Chang JG: **Fast simultaneous detection of K-RAS mutations in colorectal cancer.** *BMC Cancer* 2009, **9**:179.
37. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB: **Comparative genomic analysis of primary versus metastatic colorectal carcinomas.** *J Clin Oncol* 2012, **30**:2956–2962.
38. Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajuru S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A: **Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.** *BMC Cancer* 2013, **13**:405.
39. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgleish G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P, Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR, Futreal PA: **Recurrent KRAS codon 146 mutations in human colorectal cancer.** *Cancer Biol Ther* 2006, **5**:928–932.
40. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR: **Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.** *Br J Cancer* 2010, **102**:693–703.
41. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razi E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G: **Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.** *BMC Cancer* 2013, **13**:49.
42. Fadhil W, Ibrahim S, Seth R, AbuAli G, Ragunath K, Kaye P, Ilyas M: **The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer.** *Histopathology* 2012, **61**:1117–1124.
43. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P: **Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.** *Lancet Oncol* 2013, **14**:749–759.
44. Kosmidou V, Oikonomou E, Vlasi M, Avlonitis S, Katseli A, Tspiras I, Mourtzoukou D, Kontogeorgos G, Zografos G, Pintzas A: **Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.** *Hum Mutat* 2014, **35**:329–340.
45. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P: **KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.** *J Clin Oncol* 2009, **27**:5931–5937.
46. Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y: **Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS,**

- BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. *PLoS One* 2013, **8**:e81628.
47. Wang J, Yang H, Shen Y, Wang S, Lin D, Ma L, Han X, Shi Y: Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. *Cancer Biomark* 2013, **13**:89–97.
  48. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, Andre T, Wiezorek J, Reese D, Patterson SD: Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. *Clin Cancer Res* 2013, **19**:1902–1912.
  49. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. *BMC Cancer* 2010, **10**:101.
  50. Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, Sangkhathat S: Somatic mutations of K-Ras and BRAF in Thai colorectal cancer and their prognostic value. *Asian Pac J Cancer Prev* 2013, **14**:329–332.
  51. Sundstrom M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J: KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. *BMC Cancer* 2010, **10**:660.
  52. Lurkin I, Stoehr R, Hurst CD, van Tilborg AA, Knowles MA, Hartmann A, Zwarthoff EC: Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. *PLoS One* 2010, **5**:e8802.
  53. Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee JO, Bang SM, Park KU, Kim DW, Kang SB, Kim JS, Lee JS, Lee KW: Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. *BMC Cancer* 2012, **12**:347.
  54. Netzel BC, Grebe SK: Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. *Clin Chim Acta* 2013, **425C**:1–2.
  55. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M: Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. *Clin Cancer Res* 2011, **17**:4901–4914.
  56. Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Jung KH, Chang HJ: KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. *Int J Radiat Oncol Biol Phys* 2013, **85**:201–207.
  57. Andre T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A: Gercor. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. *Ann Oncol* 2013, **24**:412–419.
  58. Lewandowska MA, Jozwicki W, Zurawski B: KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. *Mol Diagn Ther* 2013, **17**:193–203.
  59. Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A, Lang A: Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. *Oncol Rep* 2009, **21**:1283–1287.
  60. Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, Bazan V, Agnese V, Esposito DL, De Lellis L, Semeraro D, Colucci G, Hormazdi M, Rakhshani N, Cama A, Piantelli M, Iacobelli S, Russo A, Mariani-Costantini R: Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. *Ann Oncol* 2006, **17**(Suppl 7):vii91–vii96.
  61. Luna-Perez P, Segura J, Alvarado I, Labastida S, Santiago-Payan H, Quintero A: Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. *Ann Surg Oncol* 2000, **7**:727–731.
  62. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytomaa T: p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. *Mol Pathol* 2000, **53**:24–30.
  63. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988, **319**:525–532.
  64. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. *Pathol Res Pract* 2007, **203**:489–497.
  65. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. *Nature* 1987, **327**:293–297.
  66. Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, Li MD, Fang WJ, Zheng S: Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. *World J Gastroenterol* 2011, **17**:809–816.
  67. Wistuba II, Behrens C, Albores-Saavedra J, Delgado R, Lopez F, Gazdar AF: Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. *Clin Cancer Res* 2003, **9**:3615–3619.
  68. Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirnio P, Karttunen TJ, Makinen MJ: Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. *Histopathology* 2011, **58**:679–692.
  69. Ozen F, Ozdemir S, Zemheri E, Hacimoto G, Silan F, Ozdemir O: The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. *Genet Test Mol Biomarkers* 2013, **17**:135–139.
  70. Delord JP, Taberero J, Garcia-Carbonero R, Cervantes A, Gomez-Roca C, Berge Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passiukov A, Ott MG, Soria JC: Open-label, multicentre expansion cohort to evaluate imigatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. *Eur J Cancer* 2014, **50**:496–505.
  71. Tian S, Simon I, Moreno V, Roepman P, Taberero J, Snel M, Van't Veer L, Salazar R, Bernards R, Capella G: A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. *Gut* 2013, **62**:540–549.
  72. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. *Hum Mol Genet* 2004, **13**:2303–2311.
  73. Harle A, Busser B, Rouyer M, Harter V, Genin P, Leroux A, Merlin JL: Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. *Virchows Arch* 2013, **462**:329–335.
  74. Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. *Anal Cell Pathol (Amst)* 2011, **34**:61–66.
  75. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. *J Mol Diagn* 2005, **7**:413–421.
  76. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Taberero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M: Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. *Genome Res* 2012, **22**:292–298.
  77. Gaur S, Chen L, Ann V, Lin WC, Wang Y, Chang VH, Hsu NY, Shia HS, Yen Y: Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. *Mol Cancer* 2014, **13**:21.
  78. Duan FT, Qian F, Fang K, Lin KY, Wang WT, Chen YQ: miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. *Mol Cancer* 2013, **12**:164.
  79. Guo H, Chen Y, Hu X, Qian G, Ge S, Zhang J: The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. *Mol Cancer* 2013, **12**:77.
  80. Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, Tan W, Wei G, Zhou Y: MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue

- (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. *Mol Cancer* 2013, **12**:30.
81. Zoratto F, Rossi L, Verrico M, Papa A, Basso E, Zullo A, Tomao L, Romiti A, Russo G, Tomao S: Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. *Tumour Biol* 2014. doi:10.1007/s13277-014-1845-9.
  82. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA: KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance). *Clin Cancer Res* 2014, in press.
  83. Tougeron D, Sha D, Manthravadi S, Sinicrope FA: Aspirin and colorectal cancer: back to the future. *Clin Cancer Res* 2014, **20**:1087–1094.
  84. Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S: Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BE235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. *Int J Cancer* 2013, **133**:984–996.
  85. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS: LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. *Int J Cancer* 2008, **122**:2767–2773.
  86. Bollag G, McCormick F: Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays. *Methods Enzymol* 1995, **255**:161–170.
  87. John J, Frech M, Wittinghofer A: Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. *J Biol Chem* 1988, **263**:11792–11799.
  88. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, *et al*: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. *Br J Cancer* 2001, **85**:692–696.
  89. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Goldberg RM, Bertagnolli MM, Fuchs CS, Cancer, Leukemia Group B, North Central Cancer Treatment G, Canadian Cancer Society Research I, Southwest Oncology G: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. *Clin Cancer Res* 2009, **15**:7322–7329.
  90. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. *J Clin Oncol* 2010, **28**:466–474.
  91. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. *J Clin Oncol* 2011, **29**:1261–1270.
  92. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA: KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. *Br J Cancer* 2013, **108**:1757–1764.
  93. Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. *J Cancer Res Clin Oncol* 2013, **139**:201–209.
  94. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. *Clin Cancer Res* 2009, **15**:6412–6420.

doi:10.1186/1476-4598-13-135

**Cite this article as:** Imamura *et al.*: Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. *Molecular Cancer* 2014 **13**:135.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit



